The information you provide to the chat will be recorded to improve your experience and to contact you. Please read our privacy notice to see how we are processing and protecting your data. Click to view our Cookie Notice.
We'd love your feedback—take a quick survey to help us improve.
How can we help you today?

Beyond development: Using continuous manufacturing to accelerate OSD commercialization

On-demand webinar

Continuous manufacturing is no longer just a technical ambition—it’s a strategic asset. When paired with Real-Time Release Testing (RTRT), it offers measurable advantages in speed, scalability, and quality, particularly for oral solid dose (OSD) therapies approaching commercialization.

In this webinar, Douglas B. Hausner, Ph.D., senior manager of continuous manufacturing at Thermo Fisher Scientific, shares firsthand insights from supporting the company’s first OSD product submission enabled by continuous manufacturing and RTRT—filed across major global markets including the US and EU.

Key takeaways:

  • How continuous manufacturing and RTRT enabled a successful global regulatory submission
  • How this approach can accelerate timelines, enhance product quality, and reduce scale-up complexity
  • The strategic value of integrating RTRT and continuous processes early in development
  • Lessons from Phase III through commercial launch to inform your own strategy